The Matriks Biotek SHIKARI® Q-ETA ELISA has been specially developed for the quantitative analysis of free Etanercept in serum and plasma samples.
Required Volume
Total Time
Sample
Sample Number
Detection Limit
Spike Recovery
Shelf Life
20ul
70 min
Serum, plasma
96
0.1ng/mL
85-115%
1 year
The Matriks Biotek anti-Etanercept ELISA Kit provides a tool for easily monitoring antibodies to Etanercept and exploring ways of limiting problematic immunoresponses to this drug.
SHIKARI® Q-ETA & S-ATE
Etanercept (Enbrel®)
Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma
Enzyme immunoassay for the qualitative determination of antibodies to Etanercept in serum and plasma
Required Volume
Total Time
Sample
Sample Number
Detection Limit
Spike Recovery
Shelf Life
10ul
140 min
Serum, plasma
96
+/-
-
1 year
ETA-FD-ENB: $945.00 Lead time: 1-2 weeks
ETA-QLS-ENB: $940.00 Lead time: 1-2 weeks
Peer Reviewed Journals:
Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017. **
Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014. **
Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages ** http://dx.doi.org/10.1155/2013/620837
.....................................................
.....................................................
Anti-drug Antibody Measurement
541 Taylor Way Suite# 4
San Carlos, CA 94070
Phone : (650) 486-1541
Fax : (650) 394-8638
Open weekdays 9 AM-6 PM (PST)
.........................................................................................................................................................................................................................................................